Understanding HIV drug resistance in Nigerian children on treatment
Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir use
This study is looking at why some children in Nigeria with HIV aren't getting better on their first medicine and will help find out if a different medicine called dolutegravir can work better for them by checking how the virus has changed.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10483175 on NIH RePORTER |
What this research studies
This research investigates the issue of HIV drug resistance among children in Nigeria who are not responding to their first-line antiretroviral therapy (ART). The study aims to gather critical data on acquired drug resistance (ADR) to inform the use of dolutegravir (DTG) as a second-line treatment. By analyzing the genetic makeup of the virus in these children, researchers hope to understand how existing drug resistance affects treatment outcomes. This information is vital for improving treatment strategies and ensuring better health for children living with HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are Nigerian children who are currently failing first-line ART and may require a change to second-line treatment.
Not a fit: Patients who are not living with HIV or those who are responding well to their current ART regimen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for children with HIV, improving their health outcomes and quality of life.
How similar studies have performed: Previous research has shown that understanding drug resistance patterns can significantly improve treatment outcomes, suggesting that this approach has the potential for success.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Rawizza, Holly Elizabeth — Brigham and Women's Hospital
- Study coordinator: Rawizza, Holly Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.